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Purpose of review
To bring to the attention of the clinician the metabolic
effects of most common sedatives and analgesics used in
critically ill patients.
Recent findings
Most patients admitted to the intensive care unit require
sedation and analgesia to reduce anxiety, agitation, and
delirium and provide pain relief. Inappropriate sedation and
analgesia techniques can cause harm to the already
compromised patient if they do not take into account the
metabolic effect they produce.
Summary
Metabolically critical illness can be divided in two phases,
and acute and a prolonged one. Whereas the acute or
hypermetabolic phase is characterized by elevated
circulating concentration of catabolic hormones and
substrate utilization to provide energy to vital organs, the
prolonged or catabolic phase of critical illness is marked by
reduced endocrine stimulation and severe loss of body cell
mass. The most common analgesic and sedative agents
used in the intensive care unit, if used in small or moderate
doses, do not interfere significantly with the metabolic
milieu; however, prolonged infusions, and in high doses,
without adequate monitoring of level of sedation and quality
of analgesia, can precipitate morbid events. Further
research is needed in the metabolic aspects of analgesia
and sedation in the intensive care unit, particularly if
a multimodal pharmacologic strategy is used whereby
multiple interventions aim at minimizing the risk of
overdosing and contributing to attenuation of the stress
response associated with critical illness.
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Introduction
Injury initiates a series of physiologic responses, the mag-
nitude of which depends on the intensity of the stressor.
The defense mechanisms are also related to the nature
of the injury and are activated during the initial period.
If the noxious stimulus persists, exhausting mechanisms
are initiated, leading to progressive tissue catabolism and
subsequently to death [1]. The rational use of sedatives
and analgesics can attenuate some of the most detrimental
responses and facilitate the recovery process.
Metabolic and endocrine events in
critical illness
During the first hours and days of critical illness, the de-
mand for energy by the vital organs such as the brain and
the immune system is elevated. The circulating concen-
trations of catecholamines, growth hormone, glucagon,
and cortisol are raised, whereas insulin level is depressed.
These hormones are responsible for activating hepatic
glycogenolysis and gluconeogenesis. The circulating con-
centration of glucose is increased, reflecting a state of in-
sulin resistance and incapacity by the cell to oxidize
glucose. Once hepatic glycogen is exhausted, gluconeo-
genesis is initiated with the intent to supply glucose
for those organs that depend entirely on glucose as energy
substrate. Gluconeogenic materials include amino acids
made available from the increased protein breakdown
and glycerol from lipolysis, whereas free fatty acids con-
tribute to increasing hypertriglyceridemia [2].
From a metabolic point of view, is possible to distinguish
two different phases of critical illness, an acute and a pro-
longed one. Throughout evolution, the human species has
been selected to survive disease and trauma; the acute
metabolic response is thought to be at least partially
evoked by endocrine changes, including not only an acti-
vated hypothalamic-pituitary-adrenocortical axis but also
hypersecretion of prolactin and growth hormone in the
presence of low circulating insulinlike growth factor I
(IGF-I) and a low-activity state of the thyroid and gonadal
axis. It is still unclear to what extent some of these de-
fense mechanisms may provide an exaggerated response
and, as a consequence, be harmful.
The development of intensive care medicine, with its nu-
tritional and vital organ function support, has enabled
humans to survive conditions that before were lethal.
Highly technologic interventions in the natural course
of the dying process have unmasked previously unknown
conditions, including a nonspecific wasting syndrome: de-
spite feeding, protein continues to be lost from vital organs
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and tissues due to both activated degradation and sup-
pressed synthesis, whereas reesterification (instead of oxi-
dation) of free fatty acids allows fat stores to build up.
Moreover, hyperglycemia and insulin resistance, hypopro-
teinemia, hypercalcemia, intracellular water and potassium
depletion, and hypertriglyceridemia accompany the wast-
ing, which often prompt symptomatic treatment [1].
Human data on the neuroendocrine characteristics of pro-
longed critical illness (>10 days) are now becoming avail-
able, and they appear to be quite different from those
observed in the acute phase. Whether they also represent
a beneficial adaptation or, instead, a neuroendocrine dys-
function or exhaustion is not been established. It appears
that whereas the acute phase is characterized mainly by
an actively secreting anterior pituitary gland and a periph-
eral inactivation or inactivity of anabolic hormones,
prolonged critical illness is marked by reduced neuro-
endocrine stimulation.
Insulin
The IGF binding protein number 1 (IGFBP-1) is an impor-
tant regulating mediator of the IGF bioavailability, and its
correlation with mortality has been demonstrated in critical
care patients, in whom IGF-I, IGF-II, IGFBP-1, IGFBP-2,
IGFBP-3, and IGFBP-3 protease levels are altered [3]. In
the liver, IGFBP-1 is transcriptionally suppressed by insu-
lin, and it is a specific marker of hepatic insulin sensitivity.
In patients with intensive care unit (ICU) length of stay
longer than 7 days, intensive treatment with hexogen insu-
lin (80–110 mg/dL vs 180–210 mg/dL) determined a lower-
ing of glycemia, but without effect on serum IGFBP-1,
whereas values were significantly higher in patients who
would die. The predictive value of serum IGFBP-1 is in fact
similar to the Acute Physiology and Chronic Health Eval-
uation II (APACHE-II) score [4].
Cortisol
In critically ill patients, circulating levels of cortisol are in-
creased from two to 10 times during the first 24–48 hours
of ICU stay; particularly, cortisolemia levels greater than
600 nM are related to a lower probability of survival [5].
During the prolonged phase of critical illness, conversely,
cortisol decreases, until it often becomes inadequate,
even if the hypothalamic-pituitary-adrenocortical axis
functions well [6]. The stimulating test with adrenocorti-
cotropic hormone (ACTH) can identify patients with
hypocortisolemia, in whom steroid therapy could have
a beneficial effect [7].
Thyroid hormones
The total serum concentrations of tiroxin and tri-
iodothyronine are globally decreased in critically ill pa-
tients, likely due to the reduction of thyrotropin, which
dramatically loses its pulsatile release; the nadir is reached
on average at the 4th ICU day. The altered feedback be-
tween thyrotropin-releasing hormone and thyrotropin,
‘sick euthyroid syndrome’, is associated with lethargy, ile-
us, pleural and pericardial effusions, glucose intolerance
and insulin resistance, hypertriglyceridemia, and decreas-
ing muscular protein synthesis [1]. These effects contrib-
ute to perpetuation of protein catabolism. The serum
levels of tri-iodothyronine and thyroxine in high-risk
patients are correlated with survival [5].
Growth hormone
The beneficial effects of exogenous growth hormone (from
five to 20 times the normal hematic level) could attenuate
the catabolic response, improving the protein turnover and
the nitrogen balance in burns, postsurgical, septic, and crit-
ical patients [8]. In a large randomized controlled trial per-
formed in Finland and northern Europe in 1999, however,
treatment with large doses of growth hormone increased
mortality and morbidity in adult critical patients [9].
The explanation of this result is not clear yet: growth hor-
mone causes insulin resistance and contributes to hypergly-
cemia and, moreover, prevents glutamine mobilization from
the muscle, making it less available for the fast turnover
cells such as leukocytes and enterocytes and for the hepatic
production of glutathione. Finally, the increase of multiple
organ failure, septic shock and unrestrained infections in
the treated group, leads us to think growth hormone can
worsen the immune response, changing the reactive oxygen
species and proinflammatory cytokines’ formation.
Catecholamines
The acute phase of all critical illnesses is characterized by
major catecholaminergic activation. Above all, the exces-
sive hormonal, metabolic, and inflammatory response
leads to increased oxygen consumption, hemodynamic in-
stability, intravascular fluids shifting, thermic increase,
and altered coagulation. It has already been demonstrated
that the use of most analgesic and sedative agents (fen-
tanyl, morphine, midazolam, propofol, clonidine) can con-
tribute to a decrease in hemodynamic complications [10],
modulating the serum and urine concentrations of endog-
enous catecholamines, cortisol, and dopamine.
Melatonin
Sleep disturbances are common in ICU patients, and ben-
zodiazepines, opioids, and clonidine are responsible for
a decrease in the rapid eye movement phase and in slow
wave sleep [11]. Moreover, mechanical ventilation, such
as with benzodiazepines and clonidine, abolishes the cir-
cadian rhythm of melatonin secretion [12•], whereas mor-
phine can stimulate melatonin release [13]. Delirium,
hallucinations, anxiety, and depression can also alter the
circadian rhythm of melatonin [14]. It is not known
whether treatment with melatonin could decrease the se-
verity of sleep disturbances and hence inhibit the devel-
opment of ICU delirium.
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Metabolic effects of pain
Acute experimental pain, without surgical intervention, has
been shown to activate in volunteers several changes in hor-
mone levels and metabolic pathways (insulin resistance, in-
creased plasma cortisol, catecholamines, growth hormone
and glucagon, and hyperglycemia) [15] and low oxygen ten-
sion [16]. This indicates that pain, even without inflamma-
tion, can elicit a lasting endocrine and metabolic response
of sufficient magnitude. Critically ill patients are exposed
to several stimuli of different intensity, some of them very
painful, like bronchoaspiration or tracheal extubation, which
can reach (on a Visual Analogue Scale [17] from 0–10 cm)
4.9 and 6.6 cm respectively [18]. The realization that con-
tinuous acute painful stimuli, superimposed on the nature
of injury, can enhance its physiologic and metabolic re-
sponse has prompted clinicians to attenuate this response
by introducing pharmacologic interventions.
Metabolic and endocrine effects of
analgesics and sedatives
Although the subject of analgesia and sedation has been
widely discussed in the critical care literature, little is
known about the metabolic effect of analgesics and seda-
tives used in the ICU. In addition, the potential physio-
logic repercussion these pharmacologic agents might have
on organ function and the healing process of critically ill
patients has not received adequate attention. This might
be due to the difficulty in dissecting the separate effects
of these agents when in the presence of more powerful
triggers such as inflammation, malnutrition, and immobi-
lization. Inappropriate sedation techniques that do not
take into account the possible impact on metabolic and
immune function of the critically ill patient can cause
morbidity and even mortality, as occurred with the use
of long-term infusion of the imidazole agent etomidate
in the early 1980s, and recently with large doses of pro-
pofol infusion. In this section, an attempt is made to gather
all the published information on the hormonal and meta-
bolic effects of analgesics and sedatives used in the ICU.
Inhibition or stimulation may become important clinically
when the sedative or analgesic is administered for a long
period of time, especially if changes in circulating inflam-
matory mediators have already been impaired, e.g., the ad-
renocortical response. The impact of sedation and
analgesia on some aspects of the inflammatory response
is not discussed here.
Opioids
Opioids are largely used in the ICU: they offer optimal pain
control acting mainly on gamma and kappa receptors, and
through their analgesic effect, they attenuate themetabolic
effects associated with injury. In recent clinical guidelines,
morphine, fentanyl, and hydromorphone have been recom-
mended [19]. Morphine, a water-soluble compound, is
commonly used in the ICU. It causes vasodilatation, a de-
crease in heart rate, as a result of its sympatholytic action.
Administered at high doses during cardiopulmonary bypass
grafting, morphine has been shown to inhibit circulating
concentration of catecholamines, cortisol, and growth hor-
mone. At the current moderate doses used in the ICU,
however, morphine has a minimal effect on cortisol and
no effect on plasma concentration of epinephrine [20].
Fentanyl and hydromorphone are acceptable alternatives to
morphine, with the characteristics of being synthetic and
devoid of histamine release properties. They are more
potent and cause fewer hemodynamic changes than mor-
phine, even when used in large doses. Remifentanil, an
ultrashort-acting opioid, is often used in the ICU, particu-
larly in neurocritical care, to attenuate the hemodynamic
response to painful stimuli of physiotherapy, bronchial aspi-
ration, and radiologic interventions. Remifentanil is a potent
opioid that causes hypotension and vasodilatation, probably
due to inhibition of noradrenaline. The administration of
opioids is associated with side effects such as nausea and
vomiting, itching, and ileus. Opioids have been shown to
affect the immune response and this might be undesirable
in critically ill patients who are already compromised and at
risk of acquiring opportunistic infections.
Benzodiazepines
Benzodiazepines are the most commonly used medications
for inducing sedation and treating agitation in the ICU.
These drugs promote anxiolysis, hypnosis, anticonvulsive
activity, amnesia, and skeletal muscle relaxation. They
act by potentiating g-amino butyric acid (GABA) receptor
complex-mediated inhibition of the central nervous sys-
tem. Midazolam, because of its enhanced lipophylic char-
acteristics, has a rapid onset of action with limited
effects on cardiorespiratory depression. Use of diazepam
or midazolam, together with fentanyl, maintains fairly
low endogenous levels of epinephrine and norepinephrine.
Continuous infusion of midazolam does not inhibit adreno-
cortical axis activity: cortisol secretion, studied by an
ACTH infusion test, was not inhibited [21], and plasma
catecholamine production was reduced, although not sig-
nificantly, in postoperative ventilated patients requiring in-
tensive therapy, when compared with bolus of diazepam or
sedation with isoflurane [22]. Benzodiazepines have been
shown to enhance the analgesic effects of morphine, and
this synergism may decrease the doses of benzodiazepines
needed to achieve adequate sedation. Because of the po-
tential disadvantages of continuous sedation, attempts have
been made to interrupt infusion of sedatives in critically ill
patients requiring mechanical ventilation, without major
metabolic side effects. The use of flumazenil, the specific
pharmacologic antagonist of benzodiazepines, in patients
receiving continuous sedation with midazolam is associated
with increased circulating levels of epinephrine and norepi-
nephrine. This rapid increase in plasma catecholamines is
then followed by a return to normal range within the next
2 hours; in contrast the cortisol levels remain unchanged.
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Transitory awakenings obtained with flumazenil do not in-
volve a stress response, whereas the increase in plasma cat-
echolamines suggests sympathetic nervous system activity
[23]. High doses of diazepam are associated with the devel-
opment of metabolic acidosis resulting from the propylene
glycol component of the carrier solution [24]. Similarly,
large doses of lorazepam have been shown to cause polyeth-
ylene glycol nephrotoxicity [25].
Another important aspect of benzodiazepine and opioid
long-term infusion is the withdrawal acute syndrome
[26]; common symptoms include seizures, tremor, confu-
sion, anxiety, insomnia, vomiting, tachycardia, and fever
[27]. These symptoms are more severe after cessation
of short-acting rather than long-acting benzodiazepines
[28], and for this reason, when large doses of midazolam
have been administered over long periods, the clinician
should use a tapering regimen of intravenous midazolam
over several days. Alternatively, a transition to long-acting
benzodiazepines may be of benefit.
Propofol
Propofol has been used for ICU sedation since the late
1980s and has gained popularity for its rapid onset and off-
set. As with benzodiazepines, propofol activates the GABA
receptors to produce central nervous system depression.
Propofol is cleared faster than midazolam and is rapidly
eliminated from the central compartment. Recovery times
and blood propofol concentrations were found to be similar
after 24, 48, 72, and 96 hours of drug infusion [29] with
a measurable blood concentration; for these characteristics
it is possible to modulate a more rapid weaning by mechan-
ical ventilation [30,31] and therefore a more rapid natural
endocrine/metabolic restoration. Following cardiopulmo-
nary bypass surgery, continuous infusion of propofol in
the ICU for the first postoperative 12 hours has been shown
to obtund the rise of plasma cortisol (31%) and epineph-
rine (53%), urinary cortisol (59%), dopamine (38%),
epinephrine (45%), and norepinephrine (48%) [10].
These findings indicate that intravenous propofol infusion
after cardiac surgery provides a stable hemodynamics, a de-
crease in oxygen consumption, and fewer postoperative car-
diocirculatory complications. Propofol infusion has been
shown to have no significant effects on adrenal steroidogen-
esis in critically ill patients [32]. Propofol administration
has been associated with arterial hypotension, and this is
more evident with bolus injection than with continuous
infusion. The mechanism of hypotension is peripheral va-
sodilatation, probably mediated by inhibition of noradren-
aline. No changes in heart rate have been reported. The
fall in cardiac output can also be the result of myocardial
depression. Supplementary intravenous administration of
fluid and vasopressors can be used to correct the change
in hemodynamics. Propofol is supplied in a lipidic emulsion,
and if it is infused at high doses it could lead to hypertri-
glyceridemia [33]. A randomised, multicenter study has not
been able to demonstrate a significant risk of hypertriglycer-
idemia, whether 1% or 2% propofol solutions are used [34].
It is likely that the risk will be decreased with the recently
introduced propofol 2% solution [35].
Propofol infusion syndrome
Propofol infusion syndrome is a rare and often fatal syn-
drome originally described in critically ill children and lately
reported in adults undergoing long-term (>48 hours)
propofol infusions at high doses (>4 mg/kg/h). The main
features of the syndrome are cardiac failure, rhabdomyol-
ysis, severe metabolic acidosis, and renal failure [36].
The syndrome has been reported mostly in patients with
acute neurologic illnesses or acute inflammatory diseases
complicated by severe infections or sepsis and receiving
catecholamines or steroids in addition to propofol. It is
hypothesized that central nervous system activation with
production of catecholamines and glucocorticoids, and sys-
temic inflammation with cytokine production, are priming
factors for cardiac and peripheral muscle dysfunction [37].
There is evidence that, at the subcellular level, propofol
impairs free fatty acid utilization and mitochondrial activity
with a rise in malonylcarnitine, which inhibits the transport
protein for long-chain fatty acids (carnitine palmityl trans-
ferase 1). Imbalance therefore exists between energy de-
mand and use (‘mitochondrial respiratory-chain enzyme
deficiency’): this results in a decrease in ventricular perfor-
mance and cardiac contractility [38]. This might explain
the lack of response to catecholamines and the need for in-
creasing inotropic support in these patients. Rhabdomyol-
ysis can be explained by direct myocytolytic effect of
catecholamines, resulting in myofibrillar degeneration. In
light of several reports of propofol infusion syndrome, pro-
longed high-dose propofol infusions (>80–100 mg/kg/min
for 48–72 hours) should be administered with caution
[39]. Monitoring for early signs of this syndrome (myoglo-
bin and creatine kinase levels) and the need for increasing
inotropic support have been proposed [40]. Administration
of pentobarbital may be considered alternatively, although
the potent cardiac depressant effects of this long-acting
barbiturate should be considered.
a-2 Agonists
Dexmedetomidine is a selective a-2 agonist approved for
intensive care sedation in patients receiving mechanical
ventilation. It has both analgesic and anxiolytic properties.
It is an imidazole compound with potential inhibitory
effects, similar to etomidate, on cortisol synthesis. The
latter has been demonstrated in in-vitro and in-vivo ani-
mal studies. In a recent study in which the endocrine
and inflammatory responses in patients needing postoper-
ative short-term sedation in the ICU were assessed, how-
ever, the infusion of dexmedetomidine did not inhibit
adrenal steroidogenesis [41]. This was accompanied by el-
evated circulating concentrations of growth hormone and
low insulin and catecholamines. In addition, analgesic
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opioid need was decreased with stable hemodynamics
[42]. a-2 agonists stimulate growth hormone secretion
without altering glycemic control, whereas C-peptide
(related to endogenous secretion of insulin) is decreased
[43]. This effect could be related either to the direct ac-
tion of these drugs on pancreatic islands, to better periph-
eral glycemic control with consequent decreased insulin
secretion, or to catecholamine suppression.
At present there are no data on the use of dexmedetomi-
dine for long-term sedation in the ICU. The pharmacologic
profile of a-2 agonists could make these drugs more
suitable for the ICU setting than some of the traditional
ones, in the sense that they can provide minimal sedation
with excellent analgesia, together with some attenuation
of metabolic stress response and myocardial protection. It
remains to be seen whether a-2 agonists can be safely
used during prolonged critical illness when the quality
and intensity of sedation and analgesia become critical
for the patient’s survival.
Ketamine
Ketamine is a phencyclidine derivative causing a dissocia-
tive state. It provides excellent analgesia and amnesia,
with minimal respiratory depression. It activates the sym-
pathetic nervous system resulting in an increase in heart
rate, cardiac output, and blood pressure. It is rarely used
in the ICU because of the hallucinations and emergence
delirium with which it is associated. There are some clin-
ical conditions, however, such as status asthmaticus, in
which ketamine is highly indicated for its properties as
a bronchodilator.
Etomidate
In the early 1980s, etomidate infusion in critically ill patients
was found to be associated with an unusual increase in mor-
tality [44]. Whereas etomidate given to relatively fit patients
causes a reversible adrenocortical suppression, in critically ill
patients the impaired adrenocortical synthesis of cortisol
leads to multiorgan failure and death. A single dose of eto-
midate is used for induction of anesthesia when cardiovascu-
lar stability is needed, with no ill effects. Recent studies have
also shown that administration of single-dose etomidate in
critically ill patients does not interfere with cortisol synthesis
for a certain period, although a small rise in cortisol has been
reported after ACTH stimulation, implying that there is
some residual effect on the ability of the adrenal cortex to
respond to ACTH 24 hours after a single dose [45].
Multimodal intervention: time
for consideration
It is clear from the several reports on the subject that se-
dation and analgesia of the critically ill patients represent
a challenge for the busy clinician confronted with multiple
organ failure and a limited pharmacologic armamentarium.
It appears that unimodal interventions such as propofol
or benzodiazepines have limitations and can compromise
body functions as a result of overdosing. A more global ap-
proach based on multimodal interventions would make
more sense when considering that the pathophysiology
of injury is comprised of a constellation of insults beyond
those already known (e.g., sleep disorders, hypoxia, immo-
bilization, malnutrition, autonomic imbalance), and there-
fore one drug alone cannot accomplish what is required. It
is therefore necessary to consider a different approach and
use of other medications and interventions that can be
safely introduced (of course, taking specific precautions
with the type of patient to be treated), such as epidural
local anesthetics, nonsteroidal anti-inflammatory drugs,
acetaminophen, steroids, gabapentin, and melatonin. The
possible advantage of using a multimodal approach is to de-
crease the risks associated with unimodality and to atten-
uate different stressors involved in the injury process. For
example, the use of thoracic epidural analgesia, achieved
with a mixture of local anesthetics and opioids, in the trau-
matized patient with chest, abdomen, or lower limb frac-
tures, would provide optimal analgesia, attenuate some
of the stress response associated with the injury, decrease
the hyperglycemia of trauma, facilitate lung ventilation
and oxygenation, and restore bowel function. This thera-
peutic modality could therefore be part of the multimodal
intervention aiming at treating several aspects of the path-
ophysiology beyond analgesia and sedation.
Conclusion
Some of the clinical manifestations occurring as a result of
critical illness can be attenuated by sedatives and analge-
sics, although the latter can be responsible, if not used ad-
equately, for causing harm to the already compromised
patient. Further research into multimodal intervention
is needed so that various aspects of critical illness can
be appropriately targeted and treated.
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